Study #2024-1311
A phase 3, open-label, multicenter, randomized study of xaluritamig vs cabazitaxel or second androgen receptor-directed therapy in subjects with metastatic castration-resistant prostate cancer previously treated with chemotherapy
MD Anderson Study Status
Enrolling
Treatment Agent
Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel
Description
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Castration-resistant Prostate Cancer
Study phase:
Phase III
Physician name:
Bilal Siddiqui
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-855-996-1481
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.